Jazz Pharmaceuticals Reports $4.27 Billion in Revenue for 2025, Highlights Strategic Acquisitions

**Jazz Pharmaceuticals Reports Financial Results, Highlights Strategic Advancements**

Jazz Pharmaceuticals plc (JAZZ) reported total revenues of $4.27 billion for the year ended December 31, 2025, a 5% increase compared to $4.07 billion in 2024. Net product sales reached $4.02 billion, up 5% from $3.82 billion in the previous year, driven primarily by a 12% increase in Xywav sales, which totaled $1.66 billion. This growth was attributed to increased sales volumes and a higher selling price, partially offset by higher gross to net deductions. Royalties and contract revenues totaled $245.7 million, a slight decrease of 1% compared to $247.8 million in 2024.

The company's financial performance reflected strategic shifts in its product portfolio. Xyrem sales decreased by 38% to $146.0 million, due to high-sodium oxybate competition and the adoption of Xywav by existing Xyrem patients. Epidiolex/Epidyolex sales increased by 9% to $1.06 billion, driven by increased sales volumes and a higher average selling price. The company also saw contributions from newer products, with Modeyso sales reaching $48.0 million and Ziihera sales at $24.8 million following their respective launches. Rylaze/Enrylaze sales decreased slightly by 2% to $402.9 million, while Zepzelca sales decreased by 4% to $307.3 million.

Strategic developments included the acquisition of Chimerix in April 2025 for $944.2 million, adding Modeyso to its rare oncology portfolio. In November 2024, Ziihera received accelerated approval from the FDA for the treatment of adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC). In October 2025, Zepzelca in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs was approved as a first-line maintenance treatment for adults with extensive-stage small cell lung cancer (SCLC). The company also sold its rare pediatric disease priority review voucher (PRV) in January 2026 for $200.0 million, of which 50% is attributable to Jazz.

As of December 31, 2025, Jazz Pharmaceuticals employed approximately 2,890 people worldwide, with 53% in the U.S. and 47% outside the U.S. The company's research and development activities are ongoing, with several product candidates in Phase 3 clinical trials, including zanidatamab for HER2-positive gastroesophageal adenocarcinoma (GEA) and BTC, and dordaviprone for H3 K27M-mutant diffuse glioma. Looking ahead, Jazz Pharmaceuticals anticipates increased total revenues in 2026, driven by growth in its rare oncology and epilepsy products, offset by a reduction in oxybate revenues due to generic competition. The company expects R&D expenses to increase in 2026, driven by clinical studies for zanidatamab and dordaviprone, as well as preclinical and early clinical programs.